Kibow Biotech selected present at EuroBio 2008, in Paris.
Kibow Biotech selected present at EuroBio 2008, in Paris.
PHILADELPHIA, PA - October 8, 2008 -- Kibow Biotech, Inc. is pleased to announce that it has been selected to present at the EuroBio 2008 meeting to be held in Paris, October 7-9, 2008.
Kibow Biotech, with headquarters in Newtown Square, Pennsylvania, is the only US-based company invited to this prestigious conference among fifteen selected international Bio-Pharma firms. EuroBio 2008 is considered the Life Sciences Event of the European Union Presidency. Dr. Natarajan Ranganathan, VP (R&D) and interim CEO stated, "Kibow Biotech is very excited about this opportunity to present its Enteric Dialysis™ technology and its worldwide clinical applications towards chronic kidney failure in patients. It is our intention to seek European based partners to make Kibow products available to a wider audience. Through collaboration, Kibow Biotech will establish a world-wide presence."
For more information, visit http://www.kibow.com
About Kibow Biotech
Kibow Biotech Inc. is an eleven-year-old, developing-stage biotechnology company having its operations in Newtown Square, PA, USA. The company's mission is dedicated to finding a simple, convenient and cost-effective worldwide solution for patients suffering kidney failure. The company's first generation product called Kibow Biotics(R), an orally consumable, enteric coated Gel Cap product formulation is composed of food grade microbes ("Probiotics") which metabolize the uremic toxins diffusing into the bowel as a consequence of increased levels of these toxins in the blood. It is targeted to help augment or maintain kidney function both for Chronic Kidney Disease (CKD) patients (pre-dialysis) and End Stage Renal Disease (ESRD) patients.
For additional information, contact: Dr. Natarajan Ranganathan CEO and VP Research and Development Kibow Biotech, Inc. 4629 West Chester Pike Newtown Square, PA 19073 USA Tel: (610) 353 5130 Fax: (610) 353 5110 Email address: rangan@kibowbiotech.com Web site: http://www.kibow.com
###
Forward- looking statements
Kibow Biotech company's Web site contains both historical information and also contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are not guarantees of future performance. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks, uncertainties and other factors that may cause the actual results or performance of the Company to be materially different from such statements or from any future results or performance implied thereby. Factors which could cause the Company's results or performance to differ from current expectations include, but are not limited to, timely regulatory approval of the Company's products; the ability to comply with regulatory requirements applicable to the manufacture and marketing of the Company's products; the Company's ability to obtain and enforce effective patents; the non-infringement of third party patents or proprietary rights by the Company and its products; the establishment and maintenance of strategic collaborative and commercial relationships; The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE: Kibow Biotech, Inc.
PHILADELPHIA, PA - October 8, 2008 -- Kibow Biotech, Inc. is pleased to announce that it has been selected to present at the EuroBio 2008 meeting to be held in Paris, October 7-9, 2008.
Kibow Biotech, with headquarters in Newtown Square, Pennsylvania, is the only US-based company invited to this prestigious conference among fifteen selected international Bio-Pharma firms. EuroBio 2008 is considered the Life Sciences Event of the European Union Presidency. Dr. Natarajan Ranganathan, VP (R&D) and interim CEO stated, "Kibow Biotech is very excited about this opportunity to present its Enteric Dialysis™ technology and its worldwide clinical applications towards chronic kidney failure in patients. It is our intention to seek European based partners to make Kibow products available to a wider audience. Through collaboration, Kibow Biotech will establish a world-wide presence."
For more information, visit http://www.kibow.com
About Kibow Biotech
Kibow Biotech Inc. is an eleven-year-old, developing-stage biotechnology company having its operations in Newtown Square, PA, USA. The company's mission is dedicated to finding a simple, convenient and cost-effective worldwide solution for patients suffering kidney failure. The company's first generation product called Kibow Biotics(R), an orally consumable, enteric coated Gel Cap product formulation is composed of food grade microbes ("Probiotics") which metabolize the uremic toxins diffusing into the bowel as a consequence of increased levels of these toxins in the blood. It is targeted to help augment or maintain kidney function both for Chronic Kidney Disease (CKD) patients (pre-dialysis) and End Stage Renal Disease (ESRD) patients.
For additional information, contact: Dr. Natarajan Ranganathan CEO and VP Research and Development Kibow Biotech, Inc. 4629 West Chester Pike Newtown Square, PA 19073 USA Tel: (610) 353 5130 Fax: (610) 353 5110 Email address: rangan@kibowbiotech.com Web site: http://www.kibow.com
###
Forward- looking statements
Kibow Biotech company's Web site contains both historical information and also contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are not guarantees of future performance. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks, uncertainties and other factors that may cause the actual results or performance of the Company to be materially different from such statements or from any future results or performance implied thereby. Factors which could cause the Company's results or performance to differ from current expectations include, but are not limited to, timely regulatory approval of the Company's products; the ability to comply with regulatory requirements applicable to the manufacture and marketing of the Company's products; the Company's ability to obtain and enforce effective patents; the non-infringement of third party patents or proprietary rights by the Company and its products; the establishment and maintenance of strategic collaborative and commercial relationships; The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE: Kibow Biotech, Inc.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.